17β-hsd1

11β-HSD1 inibitor 17 is an inhibitor of 11β-hydroxysteroid dehydrogenase (11β-HSD1).

17β-HSD10-IN-1 is an orally available 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10) inhibitor with blood-brain permeability and potency for the study of Alzheimer's disease.

17β-HSD10-IN-3 (compound 23) serves as an inhibitor of 17β-HSD10, exhibiting an IC50 value of 5.59 μM. Importantly, this compound demonstrates no cytotoxic effects on the HEK-293 cell line at concentrations up to 20 μM [1].

17β-HSD1-IN-1 (Compound 1) is a highly selective inhibitor of 17β-HSD1 with IC50 values of 5.6 nM for 17β-HSD1 and 3155 nM for 17β-HSD2, and it can be used in non-small cell lung cancer (NSCLC) research [1].

Steroid sulfatase/17β-HSD1-IN-1 is a highly effective inhibitor of steroid sulfatase and 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) activities, with an IC50 value of 28 nM against cellular human steroid sulfatase. This compound holds significant potential for investigating estrogen-dependent diseases [1].

Steroid sulfatase/17β-HSD1-IN-4 (compound 37) is a potent dual inhibitor of steroid sulfatase (STS) and 17β-hydroxysteroid dehydrogenase type 1 (17β HSD1). Steroid sulfatase/17β-HSD1-IN-4 irreversibly inhibits hSTS activity (IC50= 63 nM) and has research value in endometriosis and other estrogen-dependent diseases.

Steroid sulfatase/17β-HSD1-IN-3 (compound 19) is a dual inhibitor of steroid sulfatase (STS) and 17β-hydroxysteroid dehydrogenase type 1 [17β-HSD1], useful in studying endometriosis and other estrogen-dependent diseases.

Steroid sulfatase/17β-HSD1-IN-5 is an irreversible inhibitor of steroid sulfatase (STS) and a reversible, selective inhibitor of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1), with IC50 values of 43 nM for 17β-HSD1 and 6.2 μM for 17β-HSD2. This compound is utilized in research related to metabolic diseases, particularly endometriosis [1].

17β-HSD10-IN-2 (compound 11), a benzothiazolylurea-based inhibitor, specifically targets 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10), avoiding mitochondrial off-targets and cytotoxic or neurotoxic effects. This multifunctional mitochondrial enzyme inhibitor has potential applications in Alzheimer's disease (AD) and hormone-dependent cancer research [1].

AZD8329 is a selective and potent 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor that inhibits 11β-HSD2, 17β-HSD1, 17β-HSD3, and can be used for the study of allergic reactions in humans.

PBRM (17β-HSD1-IN-2) is a selective covalent inhibitor of 17β-HSD1, used in breast cancer and endometriosis research.

3-Acetyl-7-Hydroxycoumarin (Compound 2) is a highly selective inhibitor of 17-β-hydroxysteroid dehydrogenase type 1 (17β-HSD1). At a concentration of 6 μM, it achieves 57% inhibition of 17β-HSD1. 3-Acetyl-7-Hydroxycoumarin shows potential for research into hormone-dependent conditions such as breast cancer and endometriosis.

6-Bromocoumarin (compound 34) is a potential 17β-HSD1 inhibitor with affinity for α and β estrogen receptors.